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Abstract
Background: Medication errors are an important cause of morbidity and mortality in primary
care.
The aims of this study are to determine the effectiveness, cost effectiveness and acceptability of a
pharmacist-led information-technology-based complex intervention compared with simple
feedback in reducing proportions of patients at risk from potentially hazardous prescribing and
medicines management in general (family) practice.
Methods:  Research subject group: "At-risk" patients registered with computerised general
practices in two geographical regions in England.
Design: Parallel group pragmatic cluster randomised trial.
Interventions: Practices will be randomised to either: (i) Computer-generated feedback; or (ii)
Pharmacist-led intervention comprising of computer-generated feedback, educational outreach and
dedicated support.
Primary outcome measures: The proportion of patients in each practice at six and 12 months
post intervention:
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- with a computer-recorded history of peptic ulcer being prescribed non-selective non-steroidal
anti-inflammatory drugs
- with a computer-recorded diagnosis of asthma being prescribed beta-blockers
- aged 75 years and older receiving long-term prescriptions for angiotensin converting enzyme
inhibitors or loop diuretics without a recorded assessment of renal function and electrolytes in the
preceding 15 months.
Secondary outcome measures; These relate to a number of other examples of potentially
hazardous prescribing and medicines management.
Economic analysis: An economic evaluation will be done of the cost per error avoided, from the
perspective of the UK National Health Service (NHS), comparing the pharmacist-led intervention
with simple feedback.
Qualitative analysis: A qualitative study will be conducted to explore the views and experiences
of health care professionals and NHS managers concerning the interventions, and investigate
possible reasons why the interventions prove effective, or conversely prove ineffective.
Sample size: 34 practices in each of the two treatment arms would provide at least 80% power
(two-tailed alpha of 0.05) to demonstrate a 50% reduction in error rates for each of the three
primary outcome measures in the pharmacist-led intervention arm compared with a 11% reduction
in the simple feedback arm.
Discussion: At the time of submission of this article, 72 general practices have been recruited (36
in each arm of the trial) and the interventions have been delivered. Analysis has not yet been
undertaken.
Trial registration: Current controlled trials ISRCTN21785299
Background
Medication errors are an important cause of morbidity
and mortality in primary and secondary care and a
number of reports from the UK, USA and other countries
have highlighted the need to reduce error rates to prevent
patients suffering from avoidable harm[1,2].
In England, publication by the Government of An organi-
sation with a memory[1] and Building a safer NHS for
patients [3] illustrates a strong commitment to reducing
errors; the establishment of the National Patient Safety
Agency (NPSA) was a clear example of this commitment.
Recent UK government reports have suggested that while
there may still be a need to understand more about med-
ication errors and the reasons for their occurrence[3,4],
the priority now must be to find effective, acceptable and
sustainable ways of preventing patients from being
harmed as a result of errors.
Definition of error
In this study we have taken the definition of "medication
error" used by the US National Co-ordinating Council for
Medication Error Reporting and Prevention[5] and the
NPSA:
"A medication error is any preventable event that may cause or
lead to inappropriate medication use or patient harm while the
medication is in the control of health professional, patient or
consumer".
This definition thus covers the whole of the medicines
management process, from prescribing through to medi-
cation monitoring[4].
Human error theory
To understand the causes of errors it is helpful to have an
underlying theoretical framework. James Reason's work in
this field has had a major influence on our understanding
of the causes of medication errors[6]. We have, in devel-
oping our interventions, taken account of human error
theory in considering the causes of medication errors in
primary care and the approaches that are most likely to
reduce error rates.
Medication errors in primary care
This proposal builds on our narrative[7] and system-
atic[8,9] reviews of the international literature on medica-
tion errors in primary care and on our own related
empirical work [10-12]. We have drawn on these experi-
ences to identify and select outcome measures that are
clinically important. This work has shown that the follow-
ing groups of drugs are both commonly and consistentlyTrials 2009, 10:28 http://www.trialsjournal.com/content/10/1/28
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associated with medication errors that result in serious
morbidity and, in some cases, mortality:
• Cardiovascular drugs (including angiotensin converting
enzyme (ACE) inhibitors, beta-adrenoceptor blocking
drugs and diuretics)
￿ Non-steroidal anti-inflammatory drugs (NSAIDs)
￿ Oral anticoagulants (warfarin).
We have also taken account of errors associated with the
use of methotrexate, in view of warnings about this drug
from the Chief Pharmaceutical Officer for England[4],
and lithium and amiodarone because of their narrow
therapeutic indices and the need to undertake regular
blood test monitoring[13].
Underlying causes of medication errors
There have been a number of studies that have investi-
gated the underlying causes of medication errors in hospi-
tals[14,15]. Leape et al, for example, identified 16 major
systems failures from an analysis of 334 errors[14]. The
most common underlying problem was "failure of drug
knowledge dissemination" (i.e. the doctor not knowing
enough about the drug) and this accounted for 29% of
errors[14]. In contrast, Dean et al investigated the causes
of 44 prescribing errors and found that slips in attention
or failure to apply relevant rules were the commonest
underlying causes[15].
There have been relatively few detailed analyses of the
causes of medication errors in primary care although sev-
eral studies have identified the points in the medicines
management process where most errors occur[10,16]
Gurwitz  et al found that the majority of preventable
adverse drug events associated with community-based
prescribing were due to errors in the prescribing and mon-
itoring phases of pharmaceutical care[16]. These findings
were mirrored in the study of drug-related hospital admis-
sions that was undertaken in Nottingham, UK[10],
whereby 35% of admissions were thought to be due to
unsafe prescribing decisions and 26% due to inadequate
monitoring.
Our analysis of these studies suggest that in aiming to
reduce rates of medication error in primary care the key
factors that need to be addressed are:
￿ ensuring that general (family) practitioners (GPs) are
aware of the risks of the drugs most commonly associated
with adverse events
￿ ensuring that GPs recognise the hazards of rule viola-
tion, e.g. prescribing drugs that are contraindicated
￿ developing robust systems for monitoring patients on
high-risk medications (including call and recall for blood
tests) so that patients are not exposed to correctable haz-
ards.
We have taken account of these issues in the design of the
complex pharmacist-led information-technology (IT)
based intervention for our trial.
The development of methods for identifying medication 
errors using GP computer systems
The use of clinical computer systems to identify patients
with medication errors is a potentially powerful method
for "error trapping" that may allow general practices to
correct errors before patients are harmed.
We used MIQUEST[17] software successfully in our pilot
work to identify preventable drug-related morbidity in
general practice[18,19]. This process involved writing pre-
cise computer queries that are capable of extracting the
information required.
In our pilot work[18,19], we found the processing of
MIQUEST data very time-consuming. This is because it
usually involves visiting general practices to extract data
and then a considerable amount of work in processing
and checking the data. Also, it does not produce user-
friendly output for practices on individual patients who
are deemed to be "at risk".
We resolved these problems through the use of an addi-
tional type of software called Quest Browser http://
www.tcrnottingham.com. This well-established software
uses MIQUEST queries of GP computer systems, but has
several advantages over using MIQUEST alone. Firstly, it
can produce user-friendly feedback at the practice-level on
patients with medication errors (or any other clinical
problem). Secondly, output from Quest Browser can be
imported straight into a database without the need for
additional manipulation. Thirdly, Quest Browser has a
facility (called Quest Browser Central) whereby, with
agreement from the practices and research ethics commit-
tees, linked-anonymised data can be sent to researchers in
an encrypted form via the Internet. This reduces the
number of visits that researchers need to make to practices
and helps with the timely collection of data.
Development of the complex pharmacist-led IT-based 
intervention
Informed by the Medical Research Council's (MRC)
framework for complex interventions[20], we took
account of the theoretical considerations outlined above,Trials 2009, 10:28 http://www.trialsjournal.com/content/10/1/28
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along with pilot work, to develop the pharmacist-led IT-
based intervention. This is described in more detail below
(see "pharmacist-led intervention" section).
Aims of the study
To determine the effectiveness, cost effectiveness and
acceptability of a complex pharmacist-led IT-based inter-
vention compared with simple feedback in reducing pro-
portions of patients at risk from potentially hazardous
prescribing and medicines management in general prac-
tice.
Specific objectives
1. To test the hypothesis that a pharmacist-led IT-based
complex intervention using educational outreach and
practical support is more effective than simple feedback in
reducing the proportion of patients at risk from hazardous
prescribing and medicines management in general prac-
tice.
2. To conduct an economic evaluation of the cost per error
avoided, from the perspective of the NHS, of the pharma-
cist-led intervention compared with simple feedback.
3. To explore the views and experiences of health care pro-
fessionals and NHS managers concerning the interven-
tion; investigate the possible reasons why the
interventions might prove effective or ineffective, and
inform future roll-out of the pharmacist-led intervention
if it proves to be effective.
Methods/Design
Trial design
We will conduct a two-arm pragmatic cluster randomised
trial. Trial practices will receive either i) computerised
feedback on patients identified to be at risk from poten-
tially hazardous prescribing and medicines management
or ii) a complex pharmacist-led IT-based intervention in
addition to computerised feedback.
Eligibility of general practices for entering the trial
Inclusion criteria
￿ NHS general practices within a 50 mile radius of Man-
chester and Nottingham in England.
￿ Practices within NHS primary care trusts (PCTs) that
agreed to be involved in the study.
￿ Practices that were laboratory-linked (or had other reli-
able systems for recording blood test results on the prac-
tice computer system) for at least 15 months prior to the
time of baseline data collection (being laboratory-linked
means having all blood test results relayed electronically
to the practice so that these can be downloaded into
patients' computerised records).
￿ Practices that agreed to participate in the study.
Exclusion criteria
￿ Practices that stated they did not routinely record mor-
bidities such as asthma or peptic ulcer on patients' com-
puterised records.
￿ Practices not routinely using their computers to record
prescriptions issued.
￿ Practices that were intending to change their GP compu-
ter systems to that of a different supplier which was not
Quest Browser compatible during the course of the study.
￿ Practices in PCTs that were undertaking interventions
that might overlap with our intervention.
￿ Practices that were involved in the pilot study for the
trial.
￿ Practices that expected major changes in list size (num-
bers of registered patients) during the course of the study,
either because of the splitting up of the practice, merger
with other practices or any other reason for a large influx
or loss of patients.
Recruitment
General practices
We wrote to general practices in PCTs in Nottingham-
shire, Staffordshire and Central and Eastern Cheshire,
England informing them of the study. Where practices
expressed an interest in participating we arranged a face-
to-face meeting at which the study was explained in more
detail. A member of the practice team then signed a con-
sent form if the practice decided to participate. Seventy-
two general practices were recruited.
Patients
For the purposes of the health economic analysis, the gen-
eral practices recruited to the study were asked to write to
all patients identified through baseline data collection
who appeared in the numerator of one of our outcome
measures (i.e. they had potentially been subjected to haz-
ardous prescribing or medicines management). In the
accompanying patient information leaflet, patients were
given information about the study and were asked to give
consent for the research team to access their medical
records. Patients were asked to sign a consent form and to
return this to the study team.
For outcome measure six (see below for further details),
we identified some practices that keep their records of
international normalised ratio (INR) results for monitor-
ing anticoagulation therapy separate from their main
practice computer system and thus appeared to have veryTrials 2009, 10:28 http://www.trialsjournal.com/content/10/1/28
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high proportions of patients not having INRs checked
according to the computer searches we undertook. In
these cases, we did not write to patients to seek consent to
access their records because it is likely that the majority
were not at risk.
Participants for the qualitative analysis
In order to obtain a range of perspectives, purposive sam-
pling has been employed. This has enabled us to identify
a range of NHS staff (e.g. clinicians and administrative
staff) working in both the intervention and control prac-
tices in both geographical regions and in practices of var-
ying size. Also, on the basis of suggestions from trial
researchers and intervention pharmacists, we have
recruited participants with a range of viewpoints, includ-
ing those from practices where the interventions appear to
have been received positively and those where problems
have been encountered.
Other key stakeholders we have recruited include pre-
scribing and clinical governance leads of primary care
organisations, trial pharmacists, community pharmacists
and researchers closely involved in the roll-out of the
study.
We wrote to potential participants for the qualitative anal-
ysis and obtained written consent before undertaking
interviews.
Interventions
Simple feedback
Those practices randomly allocated to this arm received
computerised feedback on patients identified to be at risk
from potentially hazardous prescribing and medicines
management along with brief written educational materi-
als explaining the importance of each type of error. This
information was given to a nominated member of the
general practice (usually the practice manager) after base-
line data have been collected from the practice computer
system, using Quest Browser software.
Practices in the simple feedback arm were asked to try to
make any changes to patients' medications within a 12
week (intervention) period following the baseline data
collection.
Pharmacist intervention
Those practices randomly allocated to this arm received
simple feedback and in addition, had a complex pharma-
cist-led IT-based complex intervention.
First, the pharmacist arranged to meet with members of
the practice team to discuss the computer-generated feed-
back on patients with medication errors. All doctors were
encouraged to attend this meeting along with at least one
member of the nursing staff, the practice manager and at
least one member of the reception staff.
Before the meeting, wherever possible, all relevant mem-
bers of staff were provided with a brief summary of the
objectives of the pharmacist-led intervention and a sum-
mary of the findings from the computer search.
At the meeting the pharmacists were asked to use the fol-
lowing approach derived from the principles of educa-
tional outreach[21] while also taking account of human
error theory[6]:
￿ Establish professional credibility by explaining their
own background in clinical pharmacy and their affiliation
with either the University of Manchester or University of
Nottingham (depending on the site they are working
from)
￿ Take a non-judgemental approach in all discussions
with members of the practice team
￿ Outline the findings from the computer search
￿ Explore the views of team members about the findings
￿ Investigate the baseline knowledge of team members
regarding the importance of each of the errors
￿ Provide clear, concise, evidence-based materials on each
of the errors, encouraging active participation by team
members
￿ Explore the views of team members on the underlying
causes of the medication errors (using root-cause analysis
techniques[22] where appropriate)
￿ Explain their availability to work part-time with the
practice over the following 12 weeks to:
- Help take corrective action in individual patients
with medication errors
- Help improve the systems operating in the practice in
order to prevent future errors.
￿ Encourage the team to agree on an action plan with clear
objectives
￿ Ask for a member of the practice team to volunteer to
liaise with the pharmacist over arrangements for making
changes to individual patients' medication and introduc-
ing changes to systems within the practiceTrials 2009, 10:28 http://www.trialsjournal.com/content/10/1/28
Page 6 of 21
(page number not for citation purposes)
￿ Ask the practice to agree to a follow up meeting within
four to six weeks of the initial meeting.
Following this initial meeting, the pharmacists were
expected to use a range of techniques to help correct the
medication errors that had been identified and prevent
future medication errors. They were expected to work
closely with the practice team member assigned to pro-
vide liaison with other members of the practice.
We envisaged that the pharmacists would be taking any,
or all, of the following approaches to deal with patients
identified to be at risk from potentially hazardous pre-
scribing and medicines management:
￿ Inviting patients into the surgery for a prescription
review with the pharmacist, or a member of the general
practice team, with the aim of correcting medication
errors, e.g.
- For patients with a past history of peptic ulcer who
were being prescribed a non-selective NSAID to either:
▪ Stop the NSAID
▪ Add a proton pump inhibitor (PPI)
▪ Consider using a COX-2 inhibitor, while recog-
nising concerns about these drugs in relation to
cardiovascular risk.
- For patients with asthma who were being prescribed
a beta-blocker:
▪ In those taking beta-blocker eye drops for glau-
coma, to change to an alternative preparation
▪ In those taking oral beta-blockers, to carefully
consider the risks and benefits of the medication
and, where appropriate, slowly withdraw the drug
and replace it with an alternative preparation.
- For patients who were being prescribed methotrexate
without instructions that it should be taken weekly:
▪ Carefully check the dosage instructions
▪ Convey this information to the patient verbally
and in writing
▪ Ensure that accurate dosage instructions were
entered onto the computer system so that these
would be printed out when the drug was next
issued.
￿ Inviting the following groups of patients to have a blood
test:
- Those aged 75 years and older being prescribed ACE
inhibitors or loop diuretics who had not had a blood
test to check renal function and electrolytes within the
previous 15 months
- Those being prescribed methotrexate who had not
had a full blood count or liver function test within the
previous three months
- Those being prescribed warfarin who had not had an
INR test within the previous 12 weeks (this is the max-
imum interval recommended by the British National
Formulary[23]).
We envisaged the pharmacists taking the following
approaches to try to prevent future instances of hazardous
prescribing and medicines management, having agreed
these approaches with the practice teams:
￿ In relation to hazardous prescribing:
- Meeting up with any doctors unable to attend the ini-
tial meeting in order to provide educational outreach
- Reinforcement of educational messages provided at
the initial meeting by repeating these messages at
future meetings
- Encouraging doctors to take heed of contraindication
messages on their computer systems.
￿ In relation to inadequate blood-test monitoring:
- Encouraging practices to use their computer systems
to automatically recall patients for a blood test if they
have gone beyond a pre-specified time
- To use routine prescription reviews as the trigger for
ensuring that if patients need blood tests, these are
arranged.
Throughout the intervention period the pharmacists were
asked to maintain regular contact with the practice liaison
member of staff to facilitate changes and discuss, and
resolve, any difficulties encountered. The pharmacists
were asked to keep a written log of changes made in rela-
tion to patients with medication errors, and changes made
to practice systems.
Towards the end of the intervention period, the pharma-
cists were asked to undertake a further check of patients'
computer records to provide feedback to practices onTrials 2009, 10:28 http://www.trialsjournal.com/content/10/1/28
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progress made in correcting medication errors. They were
asked to arrange a final meeting with members of the
practice team to:
￿ Provide feedback on progress made in dealing with
patients identified to be at risk from potentially hazardous
prescribing and medicines management
￿ Provide feedback on changes made to safety systems
￿ Reinforce key educational messages
￿ Agree on an action plan for the practice to continue to
work towards reducing instances of hazardous prescribing
and medicines management.
Allocation of trial interventions
The practice was the unit of allocation. Eligible GP prac-
tices agreeing to participate in the trial were stratified by
centre (two strata: Manchester and Nottingham) and the
size of the patient population in each general practice
(three strata: <2500, 2500–6000, >6000) and randomly
allocated within strata (1:1 ratio) to the two treatment
arms.
The reason for stratifying by centre was to help ensure an
even distribution of practices allocated to each of the
intervention groups within each centre. The reason for
stratifying by size of the patient population in each gen-
eral practice was because a trial of educational outreach
suggested that the larger the practice the more difficult it
is to make changes[24].
Block randomisation, using non-predictable block sizes of
either two or four, was used to ensure a similar number of
practices in each arm. Practices were centrally randomised
as they were recruited using the independent web-based
randomisation service provided by the Clinical Trials Unit
(CTU) at the University of Nottingham. Access to the
sequence was confined to the CTU Data Manager (who
was independent from the study team). The sequence of
treatment allocations will remain concealed until all data
analyses have been completed.
Outcome measures
Outcome measures are measured at the following two
time points:
￿ Six months after the end of the intervention period
￿ 12 months after the end of the intervention period.
A summary of the main outcome measures is shown Table
1. The measures are described in more detail below.
Primary outcome measures
We are using the following primary outcome measures
based on proportions of:
1. Patients with a history of peptic ulcer who have been
prescribed a non-selective NSAID:
￿ More specifically, those with a computer-coded diag-
nosis of peptic ulcer disease, at least six months prior
to data collection, who have a computer record for one
or more prescriptions for a non-selective NSAID in the
six months prior to data collection who have not also
had a prescription for a PPI within that six month
period
￿ It should be noted that the denominator for this out-
come measure is patients with a computer-coded diag-
nosis of peptic ulcer disease, at least six months prior
to data collection, who have not also had a prescrip-
tion for a PPI in the six months prior to data collec-
tion.
2. Patients with asthma who have been prescribed a beta-
blocker:
￿ More specifically those with a computer-coded diag-
nosis of asthma, at least six months prior to data col-
lection, who have a computer record of one or more
prescriptions for a beta-blocker (oral preparations or
eye drops) in the six months prior to data collection
￿ The denominator for this outcome measure is
patients with a computer-coded diagnosis of asthma,
at least six months prior to data collection.
3. Patients aged 75 years and older who have been pre-
scribed an ACE inhibitor or a loop diuretic long-term
(see below) who have not had a computer-recorded check
of their renal function and electrolytes in the previous 15
months:
￿ More specifically, long-term prescribing implies a
first prescription for an ACE inhibitor or a loop diu-
retic at least 15 months before the time of data collec-
tion and at least one prescription in the six months
beforehand
￿ The denominator for this outcome measure is
patients aged 75 years and older who have been pre-
scribed an ACE inhibitor or a loop diuretic long-term
according to the above definition.Trials 2009, 10:28 http://www.trialsjournal.com/content/10/1/28
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Secondary outcome measures
We are collecting data on a number of secondary outcome
measures relating to contraindicated prescribing, inade-
quate monitoring and dosing problems.
Contraindicated prescribing
4. Proportions of women with a past medical history of
venous or arterial thrombosis who have been prescribed
the combined oral contraceptive pill
￿ More specifically, women with a history of venous or
arterial thrombosis recorded at least six months prior
to data collection who have a computer-recorded pre-
scription for the combined oral contraceptive pill in
the six months prior to data collection.
Inadequate monitoring
These outcomes are based on proportions of:
5. Patients receiving methotrexate  for at least three
months who have not had a recorded full blood count
and/or liver function test within the previous three
months
￿ More specifically
5a: patients with one or more prescriptions for
methotrexate recorded on computer three to six
months prior to data collection and in the three
months prior to data collection who have not had
a computer-recorded full blood count within the
previous three months
5b: patients with one or more prescriptions for
methotrexate recorded on computer three to six
months prior to data collection and in the three
months prior to data collection who have not had
a computer-recorded liver function test within the
previous three months.
6. Patients receiving warfarin for at least three months
who have not had a recorded check of their INR within the
previous 12 weeks
￿ More specifically, patients with one or more pre-
scriptions for warfarin recorded on computer three to
six months prior to data collection and in the three
months prior to data collection who have not had a
computer-recorded INR within the previous three
months.
Table 1: Summary of main outcome measures used in the trial
Outcome measure number Brief description of outcome measure
1 Patients with a history of peptic ulcerwho have been prescribed a non-selective NSAID
2 Patients with asthmawho have been prescribed a beta-blocker
3 Patients aged 75 years and older who have been prescribed an ACE inhibitor or a loop diuretic long-term who have 
not had a computer-recorded check of their renal function and electrolytes in the previous 15 months
4 Proportions of women with a past medical history of venous or arterial thrombosis who have been prescribed the 
combined oral contraceptive pill
5 Patients receiving methotrexate for at least three months who have not had a recorded full blood count and/or liver 
function test within the previous three months
6 Patients receiving warfarin for at least three months who have not had a recorded check of their INR within the 
previous 12 weeks
7 Patients receiving lithium for at least three months who have not had a recorded check of their lithium levels within 
the previous three months
8 Patients receiving amiodarone for at least six months who have not had a thyroid function test within the previous six 
months
9 Patients receiving prescriptions of methotrexate without instructions that the drug should be taken weekly
10 Patients receiving prescriptions of amiodarone for at least one month who are receiving a dose of more than 200 mg 
per dayTrials 2009, 10:28 http://www.trialsjournal.com/content/10/1/28
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7. Patients receiving lithium for at least three months who
have not had a recorded check of their lithium levels
within the previous three months
￿ More specifically, patients with one or more pre-
scriptions for lithium recorded on computer three to
six months prior to data collection and in the three
months prior to data collection who have not had a
computer-recorded lithium level within the previous
three months.
8. Patients receiving amiodarone for at least six months
who have not had a thyroid function test within the pre-
vious six months
￿ More specifically, patients with one or more pre-
scriptions for amiodarone recorded on computer 6–
12 months prior to data collection and in the three
months prior to data collection who have not had a
computer-recorded thyroid function test within the
previous six months.
Dosing problems
These outcomes are based on proportions of:
9. Patients receiving prescriptions of methotrexate with-
out instructions that the drug should be taken weekly.
￿ More specifically, patients with one or more pre-
scriptions for methotrexate recorded on computer
within the three months prior to data collection who
do not have the term "weekly" or "week" in the dosage
instructions field of the latest prescription for the drug.
10. Patients receiving prescriptions of amiodarone for at
least one month who are receiving a dose of more than
200 mg per day
￿ More specifically, patients with evidence of being
prescribed amiodarone 200 mg tablets for more than
one month in the three months prior to data collec-
tion, who do not have the term "once daily" (or simi-
lar) in the dosage instructions field for the drug.
Additional outcome measure relating to prescription of beta-blockers 
to patients with asthma
This secondary outcome measure is based on proportions
of patients with asthma who do not have coronary heart
disease (CHD) and have been prescribed a beta-blocker:
￿ More specifically those with a computer-coded diag-
nosis of asthma and no record of CHD, at least six
months prior to data collection, who have a computer
record of one or more prescriptions for a beta-blocker
(oral preparations or eye drops) in the six months
prior to data collection
￿ The denominator for this outcome measure is
patients with a computer-coded diagnosis of asthma
and no computer-coded record of CHD, at least six
months prior to data collection.
Composite outcome measures
We will also use data from the above outcome measures
to create a series of composite outcome measures (see
analysis section for further details).
Ascertainment of outcomes
Clinical outcomes
During the first three months of the study we worked with
the company that produce Quest Browser software http://
www.tcrnottingham.com to develop computerised que-
ries that would produce precisely the same types of data as
we have used in our pilot study of primary outcome meas-
ures that used QRESEARCH practices http://www.qre
search.org. We also worked with the company to produce
the outputs needed for the secondary outcome measures.
For each practice agreeing to be involved in the trial,
Quest Browser software was installed on their clinical
computer system. At the time of installation of the soft-
ware, a search of the GP computer system, using Quest
Browser was undertaken to provide anonymised baseline
data and details of individual patients at risk from poten-
tially hazardous prescribing and medicines management.
Anonymised and encrypted data pertaining to the compu-
terised primary and secondary outcomes measures are
sent via the Internet to a secure computer at the University
of Nottingham. Using Quest Browser Central software the
anonymised data are automatically imported in an Access
database along with a unique code identifying the prac-
tice.
Further data are collected at six and 12 months after the
completion of the 12-week intervention period in prac-
tices in each arm of the trial.
Issues concerning ascertainment of secondary clinical outcome 
measures
Over the course of the study we have identified issues that
may limit the validity of three of our secondary outcome
measures.
As already noted, for outcome number six, we have iden-
tified seven practices that keep their records of INR results
separate from their main practice computer system and
thus appear to have very high proportions of patients not
having INRs checked according to the computer searchesTrials 2009, 10:28 http://www.trialsjournal.com/content/10/1/28
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we have used in our study. We will need to exclude these
practices from the analysis of this outcome measure.
For outcome number nine, during the course of our study,
the NPSA required all GP computer systems to introduce
methods of ensuring that electronic prescriptions for
methotrexate gave instructions that the medication
should be taken weekly[25]. Since this change was intro-
duced our computer searches have been unable to capture
the text used to confirm the dosage instructions. Unless
we can resolve this problem it is unlikely that we will be
able to report on the follow-up data for this outcome
measure.
For outcomes nine and 10, we have found that for the
eleven practices that use the TPP computer system, we are
unable to extract information on dosage instructions. This
means that we will not be able to report on these outcome
measures for the practices in our trial that use this system.
Data for the economic analysis
Costs of the intervention
The costs measured at practice level are the costs of set-
ting-up and delivering the intervention. The costs meas-
ured at the patient level are any costs of delivering the
intervention that can be linked to individual patients.
Resources associated with providing the intervention have
been recorded, and will be combined with unit costs to
produce total costs.
Modelling economic analysis
Patients identified from the baseline computer system
searches as being at risk of potentially hazardous prescrib-
ing and medicines will be included in the modelling eco-
nomic analysis provided that they give informed consent
for researchers to view their records.
Wherever possible, data are extracted electronically,
although in the case of correspondence regarding hospital
contacts it is usually necessary to anonymise and photo-
copy relevant information. Anonymised data are sent to
the University of Nottingham where data processing and
analysis will take place.
Patients in both intervention arms will be followed up for
12 months following the completion of the intervention
in each practice. Error-related resource use data will be
collected from these patients. NHS resource use data will
be collected retrospectively for the 12 month period
before the intervention (baseline) and for 12 months after
the intervention (follow-up). Unit costs associated with
the intervention will be obtained from Personal and
Social Services Research Unit http://www.pssru.ac.uk/,
Department of Health http://www.dh.gov.uk and other
reference costs.
Data for the qualitative study
Data for the qualitative study have been obtained from:
￿ 12 initial brief interviews with NHS staff
￿ 20 in-depth interviews with NHS staff
￿ Interviews with the six trial intervention pharmacists
￿ Focus groups involving a total of 30 participants (NHS
staff and trial intervention pharmacists)
￿ Diary records kept by the six trial intervention pharma-
cists of their activities and experiences
￿ Interviews with two members of the research team
closely involved in roll-out of the trial.
Data generation continued until no new themes or issues
were emerging (saturation).
Interviews and focus groups have been digitally recorded
and transcribed and accompanying field notes have been
retained.
The specific research questions explored in the qualitative
study include the following:
￿ What are the views of primary care staff and pharma-
cists about the acceptability, effectiveness and long-
term sustainability of the trial interventions?
￿ What barriers, if any, were experienced by trial phar-
macists and primary care staff in identifying patients at
risk from potentially hazardous prescribing, in correct-
ing these problems once identified, and instituting
safer medicines management culture and policies in
the pharmacist-led IT-based intervention practice
arm?
￿ What barriers, if any, were experienced by primary
care staff in identifying patients at risk from poten-
tially hazardous prescribing, in correcting these prob-
lems once identified, and instituting safer medicines
management culture and policies in the simple feed-
back practice arm?
￿ In which ways might the trial interventions need to
be modified or adapted in order to maximise their
effectiveness when implemented in routine general
practice?
￿ What alternative interventions might be both accept-
able to key stakeholders and effective in reducing
potentially hazardous prescribing in general practice?Trials 2009, 10:28 http://www.trialsjournal.com/content/10/1/28
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Adverse events
A protocol for dealing with serious adverse events that
might occur in study practices in patients identified by the
PINCER trial outcome measures is shown in Appendix 1
(see additional file 1).
Sample size
Our sample size calculations are based on the assumption
that for the proportion of patients fulfilling the criteria for
any one of our primary outcome measures, there will be a
maximum 11% reduction in the simple feedback arm and
a 50% reduction in the pharmacist intervention arm.
Separate sample size calculations were performed for each
of the primary outcome measures (see Table 2). Sample
sizes unadjusted for clustering were calculated using the
software package nQuery Advisor® version 6.0. [26]
Data from 43 general practices contributing anonymous
clinical data to the QRESEARCH research database http://
www.qresearch.org were used to describe prevalence rates
of asthma and peptic ulcer disease and to estimate the
median proportions for each of our primary outcome
measures. The intracluster correlation coefficients (ICCs)
used in the calculation of the design effect (to inflate the
sample sizes to adjust for the cluster design)[27] were as
follows:
￿ 0.01082 for patients with a history of peptic ulcer
who have been prescribed a non-selective NSAID
(excluding those that were also in receipt of PPIs,
which would protect against the risks from NSAIDs);
￿ 0.010657 for patients with asthma who have been
prescribed a beta-blocker;
￿ 0.00952 for patients aged 75 years and older who
have been prescribed an ACE inhibitor or a loop diu-
retic long-term who have not had a computer-
recorded check of their renal function and electrolytes
in the previous 15 months.
The suggested 11% reduction in the simple feedback arm
is the equivalent to the 75% centile for changes observed
as a result of audit and feedback in a Cochrane systematic
review available at the time that we did our sample size
calculations. [28]
The suggested 50% reduction in the pharmacist interven-
tion arm of the trial is based on extrapolation from our
pilot studies[18,19] and findings from systematic reviews
and other studies that, at the time of applying for funding
for our study, showed that:
Table 2: Sample size calculations for the three primary outcome measures assuming an 11% reduction in error rates for the simple 
feedback group and a 50% reduction in error rates for the intervention group
Outcome measure Patients with a history of peptic 
ulcer who have been prescribed a 
non-selective NSAID
Patients with asthma who have 
been prescribed a beta-blocker
Patients aged 75 years and older 
prescribed an ACE inhibitor or a 
loop diuretic long-term without a 
check of their renal function and 
electrolytes in the previous 15 
months
Median error rate1
(Interquartile range)
5.76%
(3.76% – 7.85%)
1.90%
(1.27% – 3.08%)
19.80%
(15.13% – 32.69%)
Error rate in control group 
(assuming 11% reduction)
5.13% 1.69% 17.62%
Error rate in intervention group 
(assuming 50% reduction)
2.88% 0.95% 9.90%
Intraclass Correlation Coefficient 
(ICC)1
0.01082 0.00657 0.00952
Cluster size1 63 439 105
Inflation factor 1.7 3.9 2.0
Total number of practices 
required
64 66 12
1 Estimated using data obtained from 43 general practices contributing to the QResearch database http://www.qresearch.orgTrials 2009, 10:28 http://www.trialsjournal.com/content/10/1/28
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￿ Pharmacist-led interventions can lead to resolution of
medication-related problems in 55–93% of patients [29-
33]
￿ Educational outreach is a moderately powerful tool for
changing professional behaviour[34]
￿ Multifaceted interventions aimed at different barriers to
change are more effective than single interventions[35].
The calculation shown in Table 2 indicates that we would
need at least 66 practices to detect a difference between an
11% reduction in error rate in the simple feedback arm
and a 50% reduction in the intervention arm for each of
our three primary outcome measures.
On the basis of these calculations, we decided to aim to
recruit at least 68 practices. With 34 practices in each of
the two treatment arms, we would have at least 80%
power (two-tailed alpha of 0.05) to demonstrate a 50%
reduction in rates of potentially hazardous prescribing
and medicines management in the pharmacist-led arm
compared with 11% in the simple feedback arm.
Compliance
We recognise that it can be a challenge to encourage gen-
eral practices to engage in interventions. However, as the
intervention involves either simple feedback, or feedback
and the provision of a pharmacist to work with the prac-
tices, we do not expect non-compliance with the interven-
tion to be a large problem. In addition, from our
experience of the pilot study and of conducting previous
trials, we believe that the risks of non-compliance will be
minimised by providing practices with clear information
on what the study involves, providing access to members
of the research team to answer queries and address prob-
lems experienced by the practices, and support from the
PCTs.
Likely rate of loss to follow up
We do not envisage practices dropping out of the study
once they have agreed to take part. Nevertheless, at the
outset we have stressed to the practices the importance of
allowing us to collect follow-up data, even if the practice
has not engaged fully in one of the interventions. As out-
come data collection will require minimal input from the
practice or its staff, we do not foresee problems with
obtaining outcome data from participating practices.
Some patients will move practices and some will die
within the intervention period. However, this is unlikely
to have a large impact on the proportion of patients with
errors at follow-up, unless leaving the practice or death is
differentially related to medication error. This is unlikely
because the number of deaths attributable to the medica-
tion errors we are studying is likely to be small during the
course of the study. Nevertheless, we will try to follow up
patients who have died by viewing their electronic medi-
cal records up until the time of death, and requesting
paper-based records that might contain details of contacts
with secondary care.
Withdrawal of patients from the study
Withdrawal of patients consenting for their medical
records to be examined will not affect the analysis of clin-
ical outcomes as these are obtained from anonymised
computer searches of all "at risk" patients in the general
practices recruited to the study.
Withdrawal of these patients will affect the health eco-
nomic analysis although it is expected that numbers of
patients withdrawing will be small. A patient will be con-
sidered to have withdrawn from the study if the study
team receive any notification that the patient wishes to
withdraw. This notification might come from the patient
themselves, the patient's representative or from the
patient's general practice.
Statistical analysis
Data analysis, using the following analysis plan, will be
undertaken blind to treatment arm allocation (i.e. the
treatments will be identified only as A and B until analysis
is complete). The primary analysis for the clinical out-
comes used in the trial will be undertaken using the six-
month follow-up data.
Descriptive analyses
Continuous data will be explored using frequencies and
histograms and described using means and standard devi-
ations (SD) if approximately normally distributed and
medians and inter-quartile ranges (IQR) if non-normally
distributed. Categorical data will be described using fre-
quencies and percentages. Characteristics of participating
practices will be compared informally between treatment
arms.
Describing baseline characteristics of patients and practices
a) The following characteristics will be described by
treatment arm:
i) Patient age and gender
ii) Practice list size (median and IQR, or mean and
SD if normally distributed)
iii) Practice population by age group (number and
%)
iv) Practice deprivation using the Index of Multiple
Deprivation (IMD) 2004[36] (median and IQR, orTrials 2009, 10:28 http://www.trialsjournal.com/content/10/1/28
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mean and SD if normally distributed) Note this
has been calculated by multiplying the proportion
of the total list size living in each Lower Layer
Super Output Area (LSOA) by IMD 2004 LSOA
level score and then summing these across all
LSOAs in which patients registered at the practice
live.
v) Practice training status (%)
vi) Practice Quality and Outcomes Framework
(QOF) medicines management indicator points
and total QOF points[37] if available (Mean (SD
or median (IQR) dependent on distributions).
Describing baseline prevalence of medication-related problems
The following will be described using the numerator,
denominator and percentage by treatment arm, at patient
level:
i) Primary outcome measures:
Patients with a history of peptic ulcer prescribed an
NSAID without a PPI (numerator)/
Patients with a history of peptic ulcer without a PPI
(denominator)
Patients with asthma prescribed a beta-blocker
(numerator)/Patients with asthma (denominator)
Patients aged ≥75 on long term ACE inhibitors or
diuretics without urea and electrolyte monitoring
in the previous 15 months (numerator)/
Patients aged ≥75 on long term ACE inhibitors or
diuretics (denominator)
ii) Secondary outcome measures:
Patients with asthma and not CHD prescribed a
beta-blocker (numerator)/
Patients with asthma and not CHD (denominator)
Female patients with a history of venous or arterial
thromboembolism and arterial thrombosis pre-
scribed combined oral contraceptives (numera-
tor)/
Female patients with a history of venous or arterial
thromboembolism and arterial thrombosis
(denominator)
Patients prescribed methotrexate for ≥ three
months without a full blood count in last three
months (numerator)/
Patients prescribed methotrexate for ≥ three
months (denominator)
Patients prescribed methotrexate for ≥ three
months without an liver function test in last three
months (numerator)/
Patients prescribed methotrexate for ≥ three
months (denominator)
Patients prescribed warfarin for ≥ three months
without an INR in last three months (numerator)/
Patients prescribed warfarin for ≥ three months
(denominator)
Patients prescribed lithium for ≥ three months
without a lithium level in last three months
(numerator)/
Patients prescribed lithium for ≥ three months
(denominator)
Patients prescribed amiodarone for ≥ six months
without a thyroid function test in the last six
months (numerator)/
Patients prescribed amiodarone for ≥ three months
(denominator)
Patients prescribed methotrexate without instruc-
tions to take weekly (numerator)/
Patients prescribed methotrexate (denominator)
Patients prescribed amiodarone for ≥ one month
at a dose >200 mg/day (numerator)/
Patients prescribed amiodarone for ≥ one month
(denominator)
Four composite outcome measures will also be
used comprising:
Number of patients with at least one prescribing
problem (numerator)/
Number of patients at risk of at least one prescrib-
ing problem (denominator)Trials 2009, 10:28 http://www.trialsjournal.com/content/10/1/28
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Number of patients with at least one monitoring
problem (numerator)/
Number of patients at risk of at least one monitor-
ing problem (denominator)
Number of patients with at least two prescribing
problems (numerator)/
Number of patients at risk of at least two prescrib-
ing problems (denominator)
Number of patients with at least two monitoring
problems/
Number of patients at risk of at least two monitor-
ing problems (denominator)
Describing outcome data
The prevalence of each primary and secondary outcome
measure listed above will be described using numerators,
denominators and percentage by treatment arm sepa-
rately at six and 12 months follow up.
Comparing baseline characteristics between treatment 
arms
Baseline characteristics will be compared informally
between treatment arms[38].
Other baseline analyses
We may undertake other baseline analyses, and if so these
will be described in a separate analysis plan.
Comparisons between treatment arms
All outcome measures are binary in nature. They will be
compared between treatment arms using random effects
logistic regression with patient at level one and practice at
level two. Odds ratios and 95% confidence intervals will
be estimated using two-level random intercepts logistic
models, with patients at level one and practices at level
two. Models will include randomisation stratum as a fixed
effect[39]. Three separate analyses will be undertaken [40-
42]:
i) adjusting only for stratum (practice level)
ii) adjusting for stratum (practice level) and for the
presence of medication-related problems at baseline
(patient level).
iii) adjusting for stratum (practice level), baseline
medication-related problems (patient level), and dep-
rivation and training status (practice level).
An intention-to-treat analysis will be used such that prac-
tices will be analysed in the arms they were allocated to
regardless of whether they received the intervention or
not[43,44]. Significance will be assessed based on likeli-
hood ratio tests with a p value of < 0.05 taken as signifi-
cant. Analyses will be undertaken using Stata version
10[45]. Regression models adjusted for stratum and base-
line medication problem rates will yield estimates of the
cluster and residual variance components, enabling the
ICCs to be calculated [45].
Primary outcomes
The proportions of "at risk" patients in each treatment
arm with the errors of interest will be compared between
treatment arms at six and 12 months after the end of the
intervention period in each practice.
The ICC and 95% confidence interval will be estimated
for each of the primary outcome measures from the
regression models adjusted for stratum and baseline med-
ication errors.
If any practices are lost to follow up, a sensitivity analysis
will be undertaken replacing the missing follow up data
with the baseline data for that practice[43,44].
It should be noted that some patients (for both primary
and secondary outcome measures) will become "at risk"
between the time of the baseline data collection and the
follow up data collections. For the primary outcome
measures this may occur because:
￿ They have a diagnosis of asthma or peptic ulcer
recorded on the computer following the time of the
baseline data collection
￿ They reach the age of 75 years following the time of
the baseline data collection
￿ At time of the baseline data collection, they do not
fall within our definition of being prescribed an ACE
inhibitor or a loop diuretic long-term, but they do so
at the six and/or 12 month follow up data collection
points
￿ They join the practice after the time of baseline data
collection and fall within one of the "at risk" groups.
We believe that it is important to include these patients in
the analysis because the intervention is aimed not only at
correcting hazardous prescribing, but also at introducing
systems to prevent future errors. Nevertheless, for the pri-
mary outcome measures, sensitivity analysis will be
undertaken excluding patients that (for the reasons out-Trials 2009, 10:28 http://www.trialsjournal.com/content/10/1/28
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lined above) become "at risk" between the baseline data
collection and the follow up data collections.
Secondary outcome measures
The proportion of "at risk" patients in each treatment arm
with the error of interest will be compared between treat-
ment arms at six and 12 months after the end of the inter-
vention period.
We acknowledge the potential for type 1 errors associated
with significance testing for multiple end points. We will
therefore consider our analyses of secondary outcome
measures to be partly exploratory in nature, and partly
confirmatory of our findings for the primary outcome
measures.
Model checking
Level two residuals (variation between practices) for each
model will be assessed for normality and constant vari-
ance by normal plots and plotting residuals against fitted
values. The variation between practices will be summa-
rised by treatment arm[46].
Multiple endpoints
No adjustments will be made for multiple endpoints.
Findings will be interpreted with caution in view of the
number of statistical tests undertaken.
Sub-group analyses
Sub-group analyses[38] will be undertaken only for pri-
mary outcome measures. The following analyses will be
undertaken:
i) assessing whether the effect of the intervention var-
ies by practice size
ii) assessing whether the effect of the intervention var-
ies by practice deprivation
These analyses will be undertaken by incorporating a term
for the interaction between treatment arm and the (con-
tinuous) covariate of interest into the regression
model[38]. Where there is evidence of non-linearity the
covariate will be categorised at the median value. Signifi-
cance will be assessed based on likelihood ratio tests with
a p value of < 0.05 taken as significant and p values
between 0.05 and 0.1 described as there being "some evi-
dence" for an interaction.
Missing data
A complete case analysis will be undertaken at six and 12
months. If any practices are lost to follow up we will con-
sider, prior to unblinding those undertaking the analysis
to treatment group allocation, a range of approaches for
undertaking sensitivity analyses to assess the robustness of
the findings with respect to missing data.
Comparing characteristics of participating and non-
participating practices
The following characteristics will be compared between
participating and non-participating practices:
i) List size (using t test or Mann Whitney U test
dependent on distribution)
ii) Number of GPs (Mann Whitney U test)
iii) % of practice population aged ≥ 75 years (using t
test or Mann Whitney U test dependent on distribu-
tion)
iv) Training status (using χ2 test)
v) Deprivation using IMD2004 (using t test or Mann
Whitney U test dependent on distribution).
Economic analysis
We will undertake a two-stage economic analysis:
￿ A within trial analysis of cost per error avoided;
￿ A modelling analysis of economic impact of error reduc-
tion.
A standard approach to economic analysis will be
applied[47].
The principal objective of the within-trial analysis is to
identify and value the resource use associated with the
interventions used in the trial.
The principal objectives of the modelling analysis are to:
￿ Identify and value the impact on patients' health status
of the interventions;
￿ Identify and value the resource use associated with
reduced prescribing errors in primary care;
￿ Assess the relative value for money of the interventions.
Perspective
We propose to undertake the economic analyses from the
perspective of the NHS in terms of the direct costs of pro-
viding an intervention to reduce prescribing errors in gen-
eral practice.Trials 2009, 10:28 http://www.trialsjournal.com/content/10/1/28
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Comparators and key parameters under investigation
The evaluation will compare the pharmacist-led interven-
tion with simple feedback. Figure 1 illustrates the compa-
rators and the probabilistic events that are associated with
each strategy.
For the purposes of the within trial analysis of cost per
error avoided we will examine the differences in costs of
the pharmacist-based intervention compared with simple
feedback, in the context of error rate reduction.
For the modelling analysis of cost per quality adjusted life
year (QALY) gained, we will examine the differences in
overall NHS costs, in the context of QALYs gained.
Sample size for the economic analysis
The study cannot be powered to detect differences in costs
because there is no prior study upon which to base a
power calculation. From the 72 practices recruited to the
trial, just over 1000 patients (who have been identified to
be at risk from potentially hazardous prescribing or med-
icines management) have consented for the research team
to access their medical records for the purposes of the eco-
nomic analysis.
Outcome measures to be included in the economic analysis
Pilot work on data collection for the economic analysis
showed this to be very time consuming and we therefore
decided it would not be possible to collect data for all the
outcome measures. We will collect data on outcome
measures 1, 2, 3, 5, 7 and 8. We have thus decided not to
collect data for the economic analysis for outcome meas-
ures 6, 9 and 10, partly because of the problems we have
had with data ascertainment (as outlined above). In addi-
tion, the numbers of patients identified for outcome
measure four are too low to allow for meaningful within-
trial economic analysis and so this outcome measure will
also not be included.
Time horizon (follow-up period)
Error rates in practices in both groups will be followed up
for 12 months following the completion of the interven-
tion in each practice
Costs
In this cluster trial, costs will be incurred at both the
patient and cluster (practice) level. Randomising by clus-
ter can lead to imbalances between treatment arms in
practice or patient level factors, including resource use.
Costs measured at practice level
The costs measured at practice level will be the costs of
setting-up and delivering the intervention.
Costs measured at patient level
The costs measured at the patient level will be any
costs of delivering the intervention that can be linked
to individual patients.
In the modelling analysis, error-related resource use data
will be collected from patients who have consented to
access to their medical records ("consented numerator").
NHS resource use data will be collected retrospectively for
the 12 month period before the intervention (baseline)
and for 12 months after the intervention (follow-up) for
decision-analytic model of intervention to reduce preventable drug related morbidity arising from prescribing errors in general  practice Figure 1
decision-analytic model of intervention to reduce preventable drug related morbidity arising from prescribing 
errors in general practice.Trials 2009, 10:28 http://www.trialsjournal.com/content/10/1/28
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the consented numerator. This will allow us to adjust our
analyses for baseline cost[48].
Variable costs refer to items where the quantity of
resources used is determined only by the need for them as
inputs to individual patient care. Variable resource use
associated with the interventions (time spent, costs of tel-
ephone calls, printing and posting) will recorded for each
patient. Fixed costs are those costs that are not affected by
patient activity in the short term. UK standard costs will be
used for unit costs. This may somewhat over- or under-
estimate local unit costs, but allows explicit comparison
of costs and local adjustments can be made. Unit costs
associated with the intervention will be obtained from the
Personal Social Services research Unit (PSSRU)[49],
Department of Health reference tables and other reference
costs.
Within trial analysis of outcomes
Outcomes used in the within-trial analysis of cost per
error avoided will be number of prescribing errors in each
treatment arm.
Modelling analysis of outcomes
Outcomes used in the modelling analysis will be derived
from published evidence on the link between error reduc-
tion and impact on health. The PINCER study is not
designed to calculate the impact of the intervention on
patient health outcomes, either in terms of sample size or
length of follow-up. Use of proxy measures such as
number of primary and secondary care contacts (hospital
admissions, accident and emergency visits and outpatient
visits) may be subject to difficulties if considered as
patient outcomes. This is because the intervention may
lead to increased NHS contact in the short term. We will
model the long-term benefit associated with avoidance of
errors.
Literature review will be used to obtain published utility
weights to allow QALY generation and cost utility analy-
sis.
Within trial analysis of costs
Costs calculated in the within-trial analysis will be cost of
intervention for each patient enrolled in the trial for both
treatment arms. These data will be presented separately
for the two treatment arms. If required, differences in the
mean cost between the treatment arms will be estimated
using a two level random linear effects model with patient
at level one and practice at level two, to take account of the
clustered nature of the data. Baseline costs at practice level
will be included as covariates in the model. The assump-
tions for undertaking random effects linear regression will
be assessed using residual plots and in addition the
robustness of the analysis to non-normality will be
assessed by estimating 95% confidence intervals around
the difference in mean costs using bias corrected non-par-
ametric bootstrapping. If the assumptions for undertaking
random effects linear regression are not met, we will con-
sider aggregating the patient level cost data to the level of
the practice. Comparisons between treatment arms at
practice level will be made using a two sample t-test on the
original dataset, or on a bootstrapped dataset, depending
on the normality of the distribution of practice level
costs[50].
Modelling analysis of costs
The practice level cost of the intervention will be com-
bined with patient-level costs of error management. The
cost per patient will be estimated over the study period.
The costs for each event (GP surgery visit, investigations,
out of hours, accident and emergency, outpatient and
hospital admission costs) will be estimated for each
patient in the trial for both treatment arms. The costs will
be calculated as resource use multiplied by unit cost and
will be reported descriptively, both as resource use and
cost data, for each error, with means and ranges presented.
These data will be used to populate the modelling eco-
nomic analysis. Where there are gaps, these data will be
supplemented with data from the literature. Distribu-
tional forms of secondary data will follow modelling con-
vention. Literature review will be used to validate the
primary error-related resource use data and to assess any
long term resource use consequences not detected during
the study period.
Incremental cost-effectiveness ratios (ICERs)
Incremental cost effectiveness ratios will be calculated for
the trial-based analyses and sensitivity analyses.
The effectiveness measure for the calculation of incremen-
tal cost effectiveness ratio will be cost per unit of outcome.
For the within-trial analysis we will use errors. If the lower
cost intervention is also associated with better outcomes
than the more costly comparator, this will be treated as
efficient. In this scenario, incremental ratios would not be
calculated for this intervention, since its use would lead to
both net savings and greater benefits. Incremental cost
effectiveness ratios will be calculated if the higher cost
intervention is associated with better outcomes. The incre-
mental ratios will be calculated as:
Statistical analysis is not appropriate to test the robustness
of ICERs. It is not possible to generate 95% confidence
intervals around ICERs because the ratio of two distribu-
tions does not necessarily have a finite mean, or therefore,
a finite variance[50]. Therefore, generation of a bootstrap
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estimate of the ICER sampling distribution to identify the
magnitude of uncertainty around the ICERs is required.
Bootstrapping with replacement will be employed, utilis-
ing MS Excel®, using a minimum of 1000 iterations to
obtain 2.5% and 97.5% percentiles of the ICER distribu-
tion.
Cost effectiveness acceptability curves and net benefit
A cost effectiveness acceptability curve will be constructed
to express the probability that the cost per extra unit of
outcome gained from within the trial (y-axis) is cost effec-
tive as a function of the decision-maker's ceiling cost effec-
tiveness ratio (λ) (x-axis)[51]. Net benefit will be
determined when λ is £30 000. For the within-trial analy-
sis we will use cost per error avoided.
Sensitivity analysis
Sensitivity analysis is required to assess the level of uncer-
tainty in the data collected within the trial and subsequent
internal robustness of the results.
The key aspect to be investigated in this analysis will be
the impact of:
￿ size of practice
￿ alternative models of service delivery.
Format of tables for publishing the main trial results and within trial 
economic analysis
The format of tables for publishing the main trial results
and within trial economic analysis is shown in Appendix
2 (see additional file 2).
Qualitative study
The qualitative data will be subjected to thematic analysis
with the aid of NVivo® software. Actively searching for dis-
confirming data and regular detailed discussions amongst
the qualitative sub-group, and periodic discussions with
the wider multi-disciplinary steering group will help
ensure the rigour of the analysis.
Trial organisation
Professor Avery will have overall responsibility for the
day-to-day management of the trial and for the conduct of
the trial in the area around Nottingham. Professor Avery
will head the Trial Management Group.
Professor Cantrill will have overall responsibility for the
conduct of the trial in the area around Manchester.
Professor Elliott will have responsibility for the economic
analysis.
Professor Sheikh will have overall responsibility for the
conduct of the qualitative analysis and statistical advice,
which will be run from the University of Edinburgh.
Dr Sarah Armstrong is the trial statistician.
Trial Management Group
A Trial Management Group has met of a quarterly basis
throughout the study to help ensure that all trial activities
are organised according to the protocol and within the
timescales set out in the original application for funding.
Trial Steering Committee
The Trial Steering Committee (TSC) will monitor and
supervise the trial and comment on any proposed amend-
ments' to the protocol. The Trial Steering Committee is
headed by Professor Philip Hannaford. Professor Martin
Buxton and Dr Marjorie Weiss are the other external mem-
bers of the committee. The TSC and has agreed to operate
within the framework suggested in the MRC Guidelines for
good clinical practice in clinical trials [15].
Data Monitoring and Ethics Committee (DMEC)
The DMEC is headed by Professor Richard Baker. Other
external members of the committee are Professor Chris-
tine Bond and Professor Peter Donnan. The trial statisti-
cian will report to the DMEC, which will be responsible
for reviewing the data from the trial. The DMEC has
agreed to operate within the framework suggested in the
MRC Guidelines for good clinical practice in clinical trials
[15].
Ethical aspects
The clinical trial will be conducted according to the Hel-
sinki Declaration[52], the Good Clinical Practice Guide-
lines[53] and NHS Research Governance requirements.
Patients agreeing for the study team to access their clinical
records have provided written informed consent in a form
designed for such purpose. The patient may refuse to con-
tinue participating in the study at any time after providing
his/her consent.
The information generated by the study will be confiden-
tial and limited to the purposes stipulated in the protocol.
The study has been approved by Nottingham 2 Research
Ethics Committee (Reference: 05/Q2404/26). All staff
involved in data collection will have approval from the
appropriate local NHS research and development offices.
Study timeline
Trial start: 1 April 2006Trials 2009, 10:28 http://www.trialsjournal.com/content/10/1/28
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Start of baseline data collection and interventions in gen-
eral practices: August 2006
End of interventions in general practices: February 2008
End of 12 month follow-up data collection: April 2009
Start of data analysis: May 2009
Planned study end date: 30 September 2009
Duration: 3.5 years
Discussion
At the time of submission of this article, 72 general prac-
tices had been recruited (36 in each arm of the trial) and
the interventions had been completed.
In keeping with findings from our pilot studies, we have
been able to recruit general practices without too much
difficulty. It is likely that our success in recruitment relates
to the attention to detail we put into developing a feasible
intervention that was seen to be relevant to general prac-
tices, although we will find out more about whether this
was the case from our qualitative study. In addition, we
put considerable effort into our recruitment strategy
including pre-publicising the trial, sending documenta-
tion to general practices about the trial and following up
on this to arrange visits to practices where the study was
explained in more detail.
Baseline data extraction was undertaken smoothly and
successfully and provided the information needed for
practices to consider acting on patients with potentially
hazardous prescribing and medicines management. In
particular, data extraction for our pre-specified primary
outcome measures appears to have worked successfully in
all general practices recruited to the study. Nevertheless,
we have encountered some difficulties with the secondary
outcome measures, as described above. Some of these
problems could have been avoided with better foresight
on behalf of the research team. For example, had we been
aware that some general practices kept a separate record of
INR results, and did not keep these on their main clinical
computer systems, we could have excluded such practices
from our recruitment. Similarly, if we had realised that it
would not be possible to extract dosage instructions for
general practices using the TPP computer system, we
could have excluded practices using this computer system
(we did pilot our outcome measures using the TPP com-
puter system and went ahead with recruiting practices
because we erroneously believed that was a solution to the
problem). For outcome measure nine, which focused on
dosage instructions for methotrexate, a national policy
change that occurred during the course of our study has
meant that we will be unable to collect useful follow-up
data on this outcome measure for any of the practices we
have recruited. This is because the introduction of a forc-
ing function to GP computer systems, which does not
allow for anything but weekly dosing, does not appear as
a line of dosing text that can be picked up by MIQUEST
software. It is unfortunate that our study will not be able
to demonstrate the impact of this important safety initia-
tive, although it is likely that the introduction of this com-
puterised safety feature will have brought about
improvements in both arms of the trial.
At the time of submitting this protocol, analysis of quan-
titative data had not been undertaken.
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